BR112012008854A2 - combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano - Google Patents

combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano

Info

Publication number
BR112012008854A2
BR112012008854A2 BR112012008854A BR112012008854A BR112012008854A2 BR 112012008854 A2 BR112012008854 A2 BR 112012008854A2 BR 112012008854 A BR112012008854 A BR 112012008854A BR 112012008854 A BR112012008854 A BR 112012008854A BR 112012008854 A2 BR112012008854 A2 BR 112012008854A2
Authority
BR
Brazil
Prior art keywords
combination
human
pharmaceutical composition
treating cancer
kit
Prior art date
Application number
BR112012008854A
Other languages
English (en)
Other versions
BR112012008854B1 (pt
BR112012008854B8 (pt
Inventor
Melissa Dumble
Peter Lebowitz
Rakesh Kumar
Sylvie Laquerre
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43876568&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012008854(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of BR112012008854A2 publication Critical patent/BR112012008854A2/pt
Publication of BR112012008854B1 publication Critical patent/BR112012008854B1/pt
Publication of BR112012008854B8 publication Critical patent/BR112012008854B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
BR112012008854A 2009-10-16 2010-10-15 combinação, kit de combinação, uso de uma combinação, e, composição farmacêutica BR112012008854B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25221309P 2009-10-16 2009-10-16
US61/252,213 2009-10-16
PCT/US2010/052808 WO2011047238A1 (en) 2009-10-16 2010-10-15 Combination

Publications (3)

Publication Number Publication Date
BR112012008854A2 true BR112012008854A2 (pt) 2015-09-22
BR112012008854B1 BR112012008854B1 (pt) 2020-12-29
BR112012008854B8 BR112012008854B8 (pt) 2021-05-25

Family

ID=43876568

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012008854A BR112012008854B8 (pt) 2009-10-16 2010-10-15 combinação, kit de combinação, uso de uma combinação, e, composição farmacêutica

Country Status (33)

Country Link
US (3) US8703781B2 (pt)
EP (3) EP2488033B1 (pt)
JP (1) JP5718929B2 (pt)
KR (1) KR101729116B1 (pt)
CN (1) CN102655753B (pt)
AU (1) AU2010306653B2 (pt)
BR (1) BR112012008854B8 (pt)
CA (1) CA2775803C (pt)
CL (1) CL2012000964A1 (pt)
CO (1) CO6531498A2 (pt)
CR (1) CR20120155A (pt)
CY (1) CY1122013T1 (pt)
DK (2) DK3560498T3 (pt)
DO (1) DOP2012000091A (pt)
EA (1) EA020589B1 (pt)
ES (2) ES2745479T3 (pt)
HR (2) HRP20221304T1 (pt)
HU (2) HUE060206T2 (pt)
IL (1) IL219073A (pt)
LT (2) LT2488033T (pt)
MA (1) MA33746B1 (pt)
ME (1) ME03497B (pt)
MX (1) MX2012004413A (pt)
MY (1) MY174759A (pt)
NZ (1) NZ598913A (pt)
PE (1) PE20121093A1 (pt)
PL (2) PL3560498T3 (pt)
PT (2) PT3560498T (pt)
RS (2) RS59181B1 (pt)
SI (1) SI2488033T1 (pt)
UA (1) UA105064C2 (pt)
WO (1) WO2011047238A1 (pt)
ZA (1) ZA201202612B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
US9447049B2 (en) 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
ES2927660T3 (es) 2008-06-16 2022-11-10 Univ Tennessee Res Found Compuestos para el tratamiento del cáncer
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
CN103038364A (zh) * 2010-03-09 2013-04-10 达纳－法伯癌症研究所公司 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法
EP2635286A4 (en) * 2010-11-05 2014-11-12 Glaxosmithkline Ip No 2 Ltd METHOD FOR THE TREATMENT OF CANCER
TWI505828B (zh) * 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
US9580501B2 (en) 2011-12-16 2017-02-28 Synthon Biopharmaceuticals B.V. Anti-TNF alpha monoclonal secretory IgA antibodies and methods for treating inflammatory diseases
RU2014122867A (ru) * 2011-12-22 2016-02-20 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Способ лечения рака иммунотерапевтическим средством, специфичным в отношении MAGEA3, совместно с ингибитором BRAF и/или ингибитором MEK
JP2015511632A (ja) * 2012-03-30 2015-04-20 武田薬品工業株式会社 メラノーマの治療におけるｒａｆ阻害剤およびｍｅｋ阻害剤の投与
EP3981408A1 (en) * 2012-09-04 2022-04-13 Novartis AG Dabrafenib and trametinib in a method of adjuvant cancer treatment
JP2016503399A (ja) * 2012-10-25 2016-02-04 ノバルティス アーゲー 組合せ
IL266415B2 (en) 2012-11-30 2024-03-01 Glaxosmithkline Llc Innovative pharmaceutical composition
CN103965170A (zh) * 2013-01-24 2014-08-06 通化济达医药有限公司 苯磺酰胺吡唑激酶抑制剂
JP6835472B2 (ja) 2013-03-05 2021-02-24 ユニバーシティ オブ テネシー リサーチ ファウンデーション 癌の処置のための組成物
WO2014193898A1 (en) * 2013-05-31 2014-12-04 Merck Sharp & Dohme Corp. Combination therapies for cancer
EP3003282A1 (en) * 2013-06-03 2016-04-13 Novartis AG Combinations of an anti-pd-l1 antibody and a mek inhibitor and/or a braf inhibitor
WO2015003571A1 (zh) * 2013-07-08 2015-01-15 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的新晶型及其制备方法
WO2015059677A1 (en) * 2013-10-26 2015-04-30 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer
CN103588767B (zh) * 2013-11-20 2016-01-20 苏州明锐医药科技有限公司 达拉菲尼的制备方法
AU2014362995A1 (en) * 2013-12-12 2016-05-26 Novartis Ag Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer
CA2934822A1 (en) 2013-12-28 2015-07-02 Guardant Health, Inc. Methods and systems for detecting genetic variants
WO2015105822A1 (en) * 2014-01-07 2015-07-16 Glaxosmithkline Llc Cancer treatment method
MX2016014559A (es) 2014-05-06 2018-02-19 Gtx Inc Compuestos para el tratamiento de cancer.
KR101629184B1 (ko) 2014-12-10 2016-06-13 현대오트론 주식회사 Autosar 플랫폼에서의 eeprom 처리속도 향상을 위한 주기함수 호출 방법
US20190008859A1 (en) 2015-08-21 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
JP2019537604A (ja) * 2016-11-03 2019-12-26 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｅｇｆｒ／ｐｉ３ｋの小分子二重阻害剤及びその使用
CN112867803A (zh) 2018-10-16 2021-05-28 诺华股份有限公司 单独的或与免疫标志物组合的肿瘤突变负荷作为生物标志物用于预测对靶向疗法的应答
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
AU2020323033A1 (en) * 2019-07-26 2021-04-22 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical composition of MDM2 inhibitor and use thereof for preventing and/or treating disease
JP2023500906A (ja) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
JP2023506768A (ja) 2019-12-12 2023-02-20 ティン セラピューティックス エルエルシー 聴覚損失の予防及び治療のための組成物及び方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021168283A1 (en) * 2020-02-19 2021-08-26 Vanderbilt University Therapeutic methods and compositions for treating cancer using braf and/or mek inhibitor combination therapy
WO2022195551A1 (en) 2021-03-18 2022-09-22 Novartis Ag Biomarkers for cancer and methods of use thereof
CA3236424A1 (en) * 2021-11-02 2023-05-11 Verastem, Inc. Methods of treating abnormal cell growth
WO2023105286A1 (en) 2021-12-06 2023-06-15 My Personal Therapeutics Ltd A combination treatment for cancer
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
AU1623601A (en) * 1999-11-22 2001-06-04 Smithkline Beecham Plc Novel compounds
DE102004018198A1 (de) * 2004-04-15 2005-11-03 Merck Patent Gmbh Sulfonamide
RS52670B (en) * 2004-06-11 2013-06-28 Japan Tobacco Inc. 5-AMINO-2,4,7-TRIOXO-3,4,7,8-TETRAHYDRO-2H-PIRIDO (2,3-D) PYRIMIDINE DERIVATIVES AND SIMILAR COMPOUNDS FOR CANCER TREATMENT
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
WO2008120004A1 (en) * 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
EP2175885B1 (en) 2007-07-30 2016-10-12 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds

Also Published As

Publication number Publication date
KR20120104547A (ko) 2012-09-21
EP2488033A4 (en) 2014-04-30
UA105064C2 (uk) 2014-04-10
CN102655753A (zh) 2012-09-05
CN102655753B (zh) 2015-11-25
US20150111904A1 (en) 2015-04-23
MA33746B1 (fr) 2012-11-01
NZ598913A (en) 2013-11-29
DK3560498T3 (da) 2022-11-14
AU2010306653B2 (en) 2013-10-24
IL219073A (en) 2016-05-31
US20140187566A1 (en) 2014-07-03
CL2012000964A1 (es) 2012-08-31
AU2010306653A1 (en) 2012-05-10
WO2011047238A1 (en) 2011-04-21
RS59181B1 (sr) 2019-10-31
JP5718929B2 (ja) 2015-05-13
EP3560498B1 (en) 2022-08-17
PL3560498T3 (pl) 2022-12-12
CA2775803A1 (en) 2011-04-21
HUE046139T2 (hu) 2020-02-28
US8952018B2 (en) 2015-02-10
BR112012008854B1 (pt) 2020-12-29
LT2488033T (lt) 2019-09-10
CO6531498A2 (es) 2012-09-28
EP3560498A1 (en) 2019-10-30
RS63702B1 (sr) 2022-11-30
JP2013508294A (ja) 2013-03-07
EP2488033A1 (en) 2012-08-22
US20120196879A1 (en) 2012-08-02
IL219073A0 (en) 2012-06-28
DOP2012000091A (es) 2013-09-15
PL2488033T3 (pl) 2019-12-31
EP4159217A1 (en) 2023-04-05
MX2012004413A (es) 2012-05-08
US8703781B2 (en) 2014-04-22
EA201290149A1 (ru) 2012-11-30
CA2775803C (en) 2017-11-21
EA020589B1 (ru) 2014-12-30
LT3560498T (lt) 2022-11-25
DK2488033T3 (da) 2019-09-02
MY174759A (en) 2020-05-13
EP2488033B1 (en) 2019-06-12
HRP20191617T1 (hr) 2019-12-13
SI2488033T1 (sl) 2019-10-30
CR20120155A (es) 2012-07-05
ES2930157T3 (es) 2022-12-07
KR101729116B1 (ko) 2017-05-02
HUE060206T2 (hu) 2023-02-28
BR112012008854B8 (pt) 2021-05-25
ME03497B (me) 2020-04-20
PT2488033T (pt) 2019-09-10
ES2745479T3 (es) 2020-03-02
HRP20221304T1 (hr) 2022-12-23
ZA201202612B (en) 2013-09-25
PE20121093A1 (es) 2012-09-04
PT3560498T (pt) 2022-11-03
CY1122013T1 (el) 2020-10-14

Similar Documents

Publication Publication Date Title
BR112012008854A2 (pt) combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano
BRPI0811059A2 (pt) combinação, composição farmacêutica, método para tratar câncer em um animal de sangue quente, e, uso de uma combinação
BR112013019083A2 (pt) combinação de (a) um imunoconjugado, composição farmacêutica, uso de (a) um imunoconjugado, método de tratamento de uma doença em um individuo, método de estímulo de função celular efetora em um indivíduo e kit destinado ao tratamento de uma doença.
BRPI0908503A2 (pt) partícula com um diâmetro menor que 2mm, e, composição para o tratamento de tecidos
BRPI0811589A2 (pt) Composição farmacêutica e método para tratar câncer
BRPI0911685A2 (pt) composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit
EP2192889A4 (en) COSMETIC PROCESSES AND COMPOSITIONS FOR THE REPAIR OF HUMAN SKIN
IL212960A (en) Sulfonamide derivatives, the vehicle containing them and their use in cancer treatment
BRPI0809655A2 (pt) Método para tratar uma condição em um mamífero, composição farmacêutica, e, kit
BRPI0919238A2 (pt) métodos e composições para o tratamento de câncer
BR112013009142A2 (pt) "composição modeladora de fibra queratinosa, kit modelador de fibra queratinosa e métod para tratamento de uma fibra queratinosa"
BR112012018947A2 (pt) composição farmacêutica para tratamento e\ou prevenção do cancêr
DK2771041T3 (da) Sammensætninger og anvendelse deraf ved knogleheling
BR112012000417A2 (pt) aparelho para uso em tratamento terapêutico e/ou cosmético
BRPI0906576A2 (pt) Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer
BRPI0915284A2 (pt) Composição famacêutica oral, método para tratar uma infecção fúngica e para tratar câncer em um mamífero, e, formulação de liberação prolongada oral
BRPI1008566A8 (pt) métodos e composições para o diagnóstico e tratamento de câncer
BRPI1007972A2 (pt) composições de combinação e métodos para o tratamento de câncer
BRPI0909164A2 (pt) método e composições para o tratamento de câncer
BR112012029746A2 (pt) composição para tratamento da pele, método para fornecer um efeito microbicida para pele e uso de uma combinação
BR112012003842A2 (pt) composição farmacêutica, método de formulação e uso da mesma
BR112013033078A2 (pt) partícula, composição farmacêutica, conjunto para o tratamento do câncer e método para o tratamento do câncer em um paciente
BRPI1008564A2 (pt) métodos e composições para o dignóstico e tratamento de câncer
BRPI0818323A2 (pt) composição farmacêutica, uso de uma composição farmacêutica, e, método para tratar câncer.
BRPI1009741A2 (pt) composição, método para prevenir ou tratar a mucosite em paciente mamífero, composição farmacêutica para adminstração tópica, e uso de uma composição

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: GLAXO GROUP LIMITED (GB)

B25A Requested transfer of rights approved

Owner name: NOVARTIS PHARMA AG (CH)

B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/12/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/10/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B15V Prolongation of time limit allowed